Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Results of the AIM-POWER Trial

By afschroeder • February 18, 2026

DeVore AD, Majmudar M, Etters L, Xie J, Hao C, Lam PH, Hernandez AF, Fonarow GC, Desai AS. Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Results of the AIM-POWER Trial. Circ Heart Fail. 2026 Feb;19(2):e013231. doi: 10.1161/CIRCHEARTFAILURE.125.013231. Epub 2025 Dec 3. PMID: 41332416.

Tags: Cardiology/Epi, drug therapy, heart failure, implementation science, Publications, quality improvement, technology

Trinuclear Heptamethine Dyes for Shortwave Infrared In Vivo Imaging

Garcia CA, Lin EY, Mobley EB, Louie A, Hartung KM, Araujo JA, Sletten EM. Trinuclear Heptamethine Dyes for Shortwave Infrared In Vivo Imaging. Angew Chem[...]

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design

Plutzky J, Taub PR, Bhatt DL, Al Dhaybi O, Aroda VR, Basile JN, Bloch MJ, Budoff M, Busch RS, Buse JB, Cheung D, Christofides EA,[...]

Myeloid cell-specific Beta2-adrenergic receptor deletion improves early cardiac injury resolution via de-repression of Anxa1

Nayak TK, Bajpai A, Patwa V, Carter RL, Enjamuri N, Gao E, Rajan S, Xiang YK, Tilley DG. Myeloid cell-specific β2-adrenergic receptor deletion improves early[...]